Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Cross-Linked Polyphenol-Based Drug Nano-Self-Assemblies Engineered to Blockade Prostate Cancer Senescence.

Nagesh PKB, Chowdhury P, Hatami E, Kumari S, Kashyap VK, Tripathi MK, Wagh S, Meibohm B, Chauhan SC, Jaggi M, Yallapu MM.

ACS Appl Mater Interfaces. 2019 Oct 23;11(42):38537-38554. doi: 10.1021/acsami.9b14738. Epub 2019 Oct 8.

PMID:
31553876
2.

Sterilization of Mycobacterium tuberculosis infected samples using methanol preserves anti-tuberculosis drugs for subsequent pharmacological testing studies.

Walz A, Lukka PB, Pearce C, Creissen E, Braunstein M, Hickey AJ, Meibohm B, Gonzalez-Juarrero M.

Tuberculosis (Edinb). 2019 Jul;117:52-55. doi: 10.1016/j.tube.2019.06.002. Epub 2019 Jun 6.

PMID:
31378268
3.

Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599.

Stewart IE, Lukka PB, Liu J, Meibohm B, Gonzalez-Juarrero M, Braunstein MS, Lee RE, Hickey AJ.

Pharm Res. 2019 Jul 18;36(9):136. doi: 10.1007/s11095-019-2666-8.

PMID:
31321552
4.

Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants.

Jacqz-Aigrain E, Leroux S, Thomson AH, Allegaert K, Capparelli EV, Biran V, Simon N, Meibohm B, Lo YL, Marques R, Peris JE, Lutsar I, Saito J, Nakamura H, van den Anker JN, Sharland M, Zhao W.

J Antimicrob Chemother. 2019 Aug 1;74(8):2128-2138. doi: 10.1093/jac/dkz158.

PMID:
31049551
5.

Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Common Problem Drugs and How to Prescribe Them.

Donnenberg VS, Chaikin P, Mandic M, Meibohm B, van den Anker J, Rhinehart E, Nafziger AN, Burris JF; American College of Clinical Pharmacology.

J Clin Pharmacol. 2019 Jul;59(7):915-922. doi: 10.1002/jcph.1389. Epub 2019 Feb 15.

PMID:
30768795
6.

Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice.

Rathi C, Lukka PB, Wagh S, Lee RE, Lenaerts AJ, Braunstein M, Hickey A, Gonzalez-Juarrero M, Meibohm B.

Tuberculosis (Edinb). 2019 Jan;114:119-122. doi: 10.1016/j.tube.2018.12.006. Epub 2018 Dec 31.

PMID:
30711150
7.

Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis.

Vaddady PK, Trivedi A, Rathi C, Madhura DB, Liu J, Lee RE, Meibohm B.

Eur J Pharm Sci. 2019 Jan 15;127:233-239. doi: 10.1016/j.ejps.2018.11.006. Epub 2018 Nov 9.

PMID:
30419293
8.

The Journey to AAPS 2020: a Reflection from Strategic Planning to PharmSci 360.

Polli JW, McCurdy CR, Wurster DE, DeSilva BS, Bak A, Bendayan R, Meibohm B, Templeton AC, Weiser W; AAPS Leadership.

AAPS J. 2018 Nov 3;21(1):2. doi: 10.1208/s12248-018-0273-y. No abstract available.

PMID:
30392015
9.

The Journey to AAPS 2020: a Reflection from Strategic Planning to PharmSci 360.

Polli JW, McCurdy CR, Wurster DE, DeSilva BS, Bak A, Bendayan R, Meibohm B, Templeton AC, Weiser W; AAPS Leadership.

AAPS PharmSciTech. 2018 Nov;19(8):3325-3327. doi: 10.1208/s12249-018-1200-3. Epub 2018 Nov 3. No abstract available.

PMID:
30390237
10.

Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology.

Diao L, Meibohm B.

Curr Pharmacol Rep. 2018 Aug;4(4):285-291. doi: 10.1007/s40495-018-0142-5. Epub 2018 May 3.

11.

Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells.

Chowdhury P, Nagesh PKB, Hatami E, Wagh S, Dan N, Tripathi MK, Khan S, Hafeez BB, Meibohm B, Chauhan SC, Jaggi M, Yallapu MM.

J Colloid Interface Sci. 2019 Feb 1;535:133-148. doi: 10.1016/j.jcis.2018.09.072. Epub 2018 Sep 22.

PMID:
30292104
12.

Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular Mycobacterium tuberculosis.

Santos K, Lukka PB, Grzegorzewicz A, Jackson M, Trivedi A, Pavan F, Chorilli M, Braunstein M, Hickey A, Meibohm B, Gonzalez-Juarrero M.

Front Microbiol. 2018 Aug 21;9:1895. doi: 10.3389/fmicb.2018.01895. eCollection 2018.

13.

Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey.

Hohlbaum AM, Gille H, Trentmann S, Kolodziejczyk M, Rattenstetter B, Laarakkers CM, Katzmann G, Christian HJ, Andersen N, Allersdorfer A, Olwill SA, Meibohm B, Audoly LP, Swinkels DW, van Swelm RPL.

Br J Pharmacol. 2018 Apr;175(7):1054-1065. doi: 10.1111/bph.14143. Epub 2018 Feb 23.

14.

Assessment of the Drug-Drug Interaction Potential Between Theacrine and Caffeine in Humans.

He H, Ma D, Crone LB, Butawan M, Meibohm B, Bloomer RJ, Yates CR.

J Caffeine Res. 2017 Sep 1;7(3):95-102. doi: 10.1089/jcr.2017.0006.

15.

Comparison of caffeine disposition following administration by oral solution (energy drink) and inspired powder (AeroShot) in human subjects.

Laizure SC, Meibohm B, Nelson K, Chen F, Hu ZY, Parker RB.

Br J Clin Pharmacol. 2017 Dec;83(12):2687-2694. doi: 10.1111/bcp.13389. Epub 2017 Sep 5.

16.

Pharmacokinetics of Monoclonal Antibodies.

Ryman JT, Meibohm B.

CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588. doi: 10.1002/psp4.12224. Epub 2017 Jul 29. Review.

17.

Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies.

Midde NM, Gong Y, Cory TJ, Li J, Meibohm B, Li W, Kumar S.

Pharm Res. 2017 Sep;34(9):1925-1933. doi: 10.1007/s11095-017-2203-6. Epub 2017 Jun 14.

18.

Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Biologics.

Donnenberg VS, Mandic M, Rhee JC, Burns TF, Meibohm B, Korth-Bradley JM.

J Clin Pharmacol. 2017 Aug;57(8):947-955. doi: 10.1002/jcph.938. Epub 2017 Jun 14. Review.

PMID:
28614591
19.

Long Pulmonary Residence Time and Plasma Half-Life of Tiotropium: Implications for Pharmacokinetic Bioequivalence Studies.

Sharma A, Weber B, Meibohm B.

Clin Drug Investig. 2017 Jul;37(7):705-707. doi: 10.1007/s40261-017-0534-z. No abstract available.

PMID:
28567596
20.

Regulatory and Ethical Issues in Pediatric Clinical Research: Recommendations From a Panel Discussion.

Kshirsagar N, Swaminathan S, Jog P, Dalwai S, Mathur R, Shekhar C, Meibohm B, Gupta YK, Shafiq N, Sunkara G, Somani VG, Kulkarni P, Tseng B, Mehta D.

J Clin Pharmacol. 2017 Aug;57(8):943-946. doi: 10.1002/jcph.916. Epub 2017 May 17. Review. No abstract available.

PMID:
28513861
21.

A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.

Siricilla S, Mitachi K, Yang J, Eslamimehr S, Lemieux MR, Meibohm B, Ji Y, Kurosu M.

J Med Chem. 2017 Apr 13;60(7):2869-2878. doi: 10.1021/acs.jmedchem.6b01805. Epub 2017 Mar 22.

22.

Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells.

Midde NM, Sinha N, Lukka PB, Meibohm B, Kumar S.

PLoS One. 2017 Feb 23;12(2):e0172628. doi: 10.1371/journal.pone.0172628. eCollection 2017.

23.

Structure-Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions.

Liu J, Bruhn DF, Lee RB, Zheng Z, Janusic T, Scherbakov D, Scherman MS, Boshoff HI, Das S, Rakesh, Waidyarachchi SL, Brewer TA, Gracia B, Yang L, Bollinger J, Robertson GT, Meibohm B, Lenaerts AJ, Ainsa J, Böttger EC, Lee RE.

ACS Infect Dis. 2017 Jan 13;3(1):72-88. doi: 10.1021/acsinfecdis.6b00158. Epub 2016 Nov 11.

24.

Immune Suppression During Preclinical Drug Development Mitigates Immunogenicity-Mediated Impact on Therapeutic Exposure.

Herskovitz J, Ryman J, Thway T, Lee S, Zhou L, Chirmule N, Meibohm B, Jawa V.

AAPS J. 2017 Mar;19(2):447-455. doi: 10.1208/s12248-016-0026-8. Epub 2017 Jan 9.

PMID:
28070711
25.

Translational PK/PD of anti-infective therapeutics.

Rathi C, Lee RE, Meibohm B.

Drug Discov Today Technol. 2016 Sep - Dec;21-22:41-49. doi: 10.1016/j.ddtec.2016.08.004. Epub 2016 Oct 28. Review.

26.

Drug Development of Therapeutic Monoclonal Antibodies.

Mould DR, Meibohm B.

BioDrugs. 2016 Aug;30(4):275-93. doi: 10.1007/s40259-016-0181-6. Review.

PMID:
27342605
27.

Challenges and Opportunities for Increasing the Knowledge Base Related to Drug Biotransformation and Pharmacokinetics during Growth and Development.

Leeder JS, Meibohm B.

Drug Metab Dispos. 2016 Jul;44(7):916-23. doi: 10.1124/dmd.116.071159. Review.

PMID:
27302933
28.

Essential criteria for pharmacokinetic studies supporting bioequivalence of inhaled tiotropium bromide products.

Sharma A, Weber B, Wein M, Hallmann C, Meibohm B.

Clin Pharmacol Drug Dev. 2016 Jan;5(1):52-6. doi: 10.1002/cpdd.187. Epub 2015 Jun 2. No abstract available.

PMID:
27119578
29.

Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric Liver.

Thomson MM, Hines RN, Schuetz EG, Meibohm B.

Drug Metab Dispos. 2016 Jul;44(7):999-1004. doi: 10.1124/dmd.115.069252. Epub 2016 Apr 20.

30.
31.

Tissue Penetration of a Novel Spectinamide Antibiotic for the Treatment of Tuberculosis.

Madhura DB, Trivedi A, Liu J, Boyd VA, Jeffries C, Loveless V, Lee RE, Meibohm B.

AAPS J. 2016 May;18(3):788-91. doi: 10.1208/s12248-016-9900-7. Epub 2016 Mar 16.

32.

Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method.

Midde NM, Rahman MA, Rathi C, Li J, Meibohm B, Li W, Kumar S.

PLoS One. 2016 Feb 12;11(2):e0149225. doi: 10.1371/journal.pone.0149225. eCollection 2016.

33.

Urinary metabolites from mango (Mangifera indica L. cv. Keitt) galloyl derivatives and in vitro hydrolysis of gallotannins in physiological conditions.

Barnes RC, Krenek KA, Meibohm B, Mertens-Talcott SU, Talcott ST.

Mol Nutr Food Res. 2016 Mar;60(3):542-50. doi: 10.1002/mnfr.201500706. Epub 2016 Feb 2.

PMID:
26640139
34.

From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals.

Gunn GR 3rd, Sealey DC, Jamali F, Meibohm B, Ghosh S, Shankar G.

Clin Exp Immunol. 2016 May;184(2):137-46. doi: 10.1111/cei.12742. Epub 2016 Jan 19. Review.

35.

In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics.

Bruhn DF, Scherman MS, Liu J, Scherbakov D, Meibohm B, Böttger EC, Lenaerts AJ, Lee RE.

Sci Rep. 2015 Sep 14;5:13985. doi: 10.1038/srep13985.

36.

Pattern Recognition in Pharmacokinetic Data Analysis.

Gabrielsson J, Meibohm B, Weiner D.

AAPS J. 2016 Jan;18(1):47-63. doi: 10.1208/s12248-015-9817-6. Epub 2015 Sep 3. Review.

37.

Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist.

Presley C, Abidi A, Suryawanshi S, Mustafa S, Meibohm B, Moore BM.

Pharmacol Res Perspect. 2015 Aug;3(4):e00159. doi: 10.1002/prp2.159. Epub 2015 Jul 6.

38.

Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group.

Brouwer KL, Aleksunes LM, Brandys B, Giacoia GP, Knipp G, Lukacova V, Meibohm B, Nigam SK, Rieder M, de Wildt SN; Pediatric Transporter Working Group.

Clin Pharmacol Ther. 2015 Sep;98(3):266-87. doi: 10.1002/cpt.176. Review.

39.

Aminomethyl spectinomycins as therapeutics for drug-resistant respiratory tract and sexually transmitted bacterial infections.

Bruhn DF, Waidyarachchi SL, Madhura DB, Shcherbakov D, Zheng Z, Liu J, Abdelrahman YM, Singh AP, Duscha S, Rathi C, Lee RB, Belland RJ, Meibohm B, Rosch JW, Böttger EC, Lee RE.

Sci Transl Med. 2015 May 20;7(288):288ra75. doi: 10.1126/scitranslmed.3010572.

40.

Tools for predicting the PK/PD of therapeutic proteins.

Diao L, Meibohm B.

Expert Opin Drug Metab Toxicol. 2015 Jul;11(7):1115-25. doi: 10.1517/17425255.2015.1041917. Epub 2015 May 4. Review.

PMID:
25936400
41.

Clinical pharmacology of bispecific antibody constructs.

Rathi C, Meibohm B.

J Clin Pharmacol. 2015 Mar;55 Suppl 3:S21-8. doi: 10.1002/jcph.445. Review.

PMID:
25707960
42.

Challenges and considerations for development of therapeutic proteins in pediatric patients.

Zhang Y, Wei X, Bajaj G, Barrett JS, Meibohm B, Joshi A, Gupta M.

J Clin Pharmacol. 2015 Mar;55 Suppl 3:S103-15. doi: 10.1002/jcph.382. Review.

PMID:
25707958
43.

Ethanol lock therapy: a pilot infusion study in infants.

Chhim RF, Crill CM, Collier HK, Arnold SR, Pourcyrous M, Meibohm B, Christensen M.

Ann Pharmacother. 2015 Apr;49(4):431-6. doi: 10.1177/1060028015569881. Epub 2015 Jan 28.

PMID:
25632063
44.

Effects of alcohol on human carboxylesterase drug metabolism.

Parker RB, Hu ZY, Meibohm B, Laizure SC.

Clin Pharmacokinet. 2015 Jun;54(6):627-38. doi: 10.1007/s40262-014-0226-2.

45.

Protein engineering for improved pharmacologic characteristics of established monoclonal antibody-based therapeutics.

Meibohm B.

Clin Pharmacokinet. 2014 Oct;53(10):863-4. doi: 10.1007/s40262-014-0186-6. No abstract available.

PMID:
25212704
46.

Large-scale genome-wide association studies and meta-analyses of longitudinal change in adult lung function.

Tang W, Kowgier M, Loth DW, Soler Artigas M, Joubert BR, Hodge E, Gharib SA, Smith AV, Ruczinski I, Gudnason V, Mathias RA, Harris TB, Hansel NN, Launer LJ, Barnes KC, Hansen JG, Albrecht E, Aldrich MC, Allerhand M, Barr RG, Brusselle GG, Couper DJ, Curjuric I, Davies G, Deary IJ, Dupuis J, Fall T, Foy M, Franceschini N, Gao W, Gläser S, Gu X, Hancock DB, Heinrich J, Hofman A, Imboden M, Ingelsson E, James A, Karrasch S, Koch B, Kritchevsky SB, Kumar A, Lahousse L, Li G, Lind L, Lindgren C, Liu Y, Lohman K, Lumley T, McArdle WL, Meibohm B, Morris AP, Morrison AC, Musk B, North KE, Palmer LJ, Probst-Hensch NM, Psaty BM, Rivadeneira F, Rotter JI, Schulz H, Smith LJ, Sood A, Starr JM, Strachan DP, Teumer A, Uitterlinden AG, Völzke H, Voorman A, Wain LV, Wells MT, Wilk JB, Williams OD, Heckbert SR, Stricker BH, London SJ, Fornage M, Tobin MD, O'Connor GT, Hall IP, Cassano PA.

PLoS One. 2014 Jul 1;9(7):e100776. doi: 10.1371/journal.pone.0100776. eCollection 2014.

47.

The challenge of indication extrapolation for infliximab biosimilars.

Feagan BG, Choquette D, Ghosh S, Gladman DD, Ho V, Meibohm B, Zou G, Xu Z, Shankar G, Sealey DC, Russell AS.

Biologicals. 2014 Jul;42(4):177-83. doi: 10.1016/j.biologicals.2014.05.005. Epub 2014 Jun 21. Review.

48.

Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis.

Rakesh, Bruhn DF, Scherman MS, Woolhiser LK, Madhura DB, Maddox MM, Singh AP, Lee RB, Hurdle JG, McNeil MR, Lenaerts AJ, Meibohm B, Lee RE.

PLoS One. 2014 Feb 5;9(2):e87909. doi: 10.1371/journal.pone.0087909. eCollection 2014.

49.

Novel endogenous glycan therapy for retinal diseases: safety, in vitro stability, ocular pharmacokinetic modeling, and biodistribution.

Swaminathan S, Li H, Palamoor M, de Obarrio WT, Madhura D, Meibohm B, Jablonski MM.

AAPS J. 2014 Mar;16(2):311-23. doi: 10.1208/s12248-014-9563-1. Epub 2014 Jan 28.

50.

Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux.

Lee RE, Hurdle JG, Liu J, Bruhn DF, Matt T, Scherman MS, Vaddady PK, Zheng Z, Qi J, Akbergenov R, Das S, Madhura DB, Rathi C, Trivedi A, Villellas C, Lee RB, Rakesh, Waidyarachchi SL, Sun D, McNeil MR, Ainsa JA, Boshoff HI, Gonzalez-Juarrero M, Meibohm B, Böttger EC, Lenaerts AJ.

Nat Med. 2014 Feb;20(2):152-158. doi: 10.1038/nm.3458. Epub 2014 Jan 26.

Supplemental Content

Loading ...
Support Center